Nemolizumab for adults with scleroderma
Treatments studied
Part of Lungs & breathing, Skin clinical trials.
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of systemic sclerosis (scleroderma).
- Your skin thickening must be moderate (score between 12 and 30 if you have diffuse type, or 8 or more if limited type, and you must not have anti-centromere antibodies if limited).
- Your disease must be early (within 5 years for diffuse, or 2 years for limited).
- You may be on stable doses of methotrexate, mycophenolate, or nintedanib for at least 3 months.
- You cannot have certain other autoimmune diseases, severe organ damage, or recent infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study tests an experimental cell therapy that targets your own immune cells to treat systemic sclerosis (scleroderma) with lung involvement. It aims to see if this treatment works better than standard care in reducing disease activity.
This study tests a new injectable medicine (nemolizumab) for people with moderate-to-severe eczema that hasn't been helped enough by topical treatments. It aims to reduce itching and skin symptoms. The trial will compare the drug to a placebo in Chinese participants.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
This trial tests a medication called obinutuzumab to see if it can help people with systemic sclerosis (a disease that causes hardening of the skin and organs). It may reduce skin thickening and slow disease progression.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.